Volume 10, Issue 4 (12-2022)                   J. Pediatr. Rev 2022, 10(4): 277-286 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nasri P, Sadeghi S, Hovsepian S, Chegini R, Soltani Esmaeili S, Kiani G. COVID-19 in Children With Inflammatory Bowel Disease: A Systematic Review. J. Pediatr. Rev 2022; 10 (4) :277-286
URL: http://jpr.mazums.ac.ir/article-1-476-en.html
1- Metabolic Liver Disease Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
2- Acquired Immunodeficiency Research Center, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
3- Department of Pediatrics, School of Medicine, Imam Hossein Children’s Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
4- Department of Pediatrics, School of Medicine, Imam Hossein Children’s Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. , goli2291@yahoo.com
Abstract:   (486 Views)
Background: Considering the chronic immunosuppression in Inflammatory Bowel Disease (IBD) patients, it is necessary to evaluate the course of COVID-19 in these patients. Studies have shown various results in adult IBD patients. This study aimed to find out the course of this infection in pediatric IBD patients. 
Methods: This was a systematic review study according to the PRISMA 2020 guideline. International databases including Scopus, PubMed, and the Web of Science were searched with a combination of “COVID-19” AND “IBD” or synonyms until October 16, 2021. Studies that have reported the outcomes of COVID-19 infection in patients less than 19 years of age were selected. Name of author, country, study duration and type, IBD type and drugs, and COVID-19 outcomes were extracted.
Results: From the initially retrieved 2215 articles, finally 16 articles were eligible. Data from 1040 pediatric IBD patients were reported. Twenty-four patients were hospitalized, 5 developed patients multisystem inflammatory syndrome in children, and others had a mild disease course and were outpatient. Steroid use, severe IBD activity, and comorbidities were shown to increase risk of hospitalization and disease severity.
Conclusions: COVID-19 is a benign and self-limited disease in pediatric IBD patients. Comorbidities, steroid use, and severe IBD activity affect the outcomes.
Full-Text [PDF 534 kb]   (237 Downloads) |   |   Full-Text (HTML)  (52 Views)  
Type of Study: Systematic Review | Subject: Pediatric Gastroenterology
Received: 2022/06/6 | Accepted: 2022/08/10 | Published: 2022/12/19

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Pediatrics Review

Designed & Developed by : Yektaweb